Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations.
The management of central diabetes insipidus has been greatly simplified by the introduction of desmopressin (DDAVP). Its ease of administration, safety and tolerability make DDAVP the first line agent for outpatient treatment of central diabetes insipidus. The major complication of DDAVP therapy is water intoxication and hyponatremia. The risk of hyponatremia can be reduced by careful dose titration when initiating therapy and by close monitoring of serum osmolality when DDAVP is used with other medications affecting water balance. Herein we review the adverse effects of DDAVP and its predecessor, vasopressin, as well as discuss important clinical considerations when using these agents to treat central diabetes insipidus.
Kim
Roy J
RJ
Division of Endocrinology (R.J.K, T.M.), Department of Pediatrics, The Children's Hospital of Philadelphia, The University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Malattia
Clara
C
Allen
Michaela
M
Moshang
Thomas
T
Maghnie
Mohamad
M
D050034:Antidiuretic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000009:adverse effects*; D020790:Diabetes Insipidus, Neurogenic / Q000188:drug therapy*; D006801:Humans; D014667:Vasopressins / Q000008:administration & dosage / Q000009:adverse effects
D050034:Antidiuretic Agents; D014667:Vasopressins; D003894:Deamino Arginine Vasopressin